A prospective registry analysis showed that the levels of LDL-C at evolocumab initiation were nearly three times higher than the recommended European threshold for initiation of PCSK9 inhibitors, even though treatment was associated with improved outcomes.13 Increasing awareness of the efficacy of PCSK9 inhibitors and identifying the appropriate patients who can benefit from treatment may help to reduce the burden of hyperlipidaemia and associated CV risk factors or diseases. The gene discussed is PCSK9; the disease is hyperlipidemia.